

Publikationen Neurologie 2018

1. Adriani M, Nytrova P, Mbogning C, Hässler S, Medek K, Jensen PEH, Creeke P, Warnke C, Ingenhoven K, Hemmer B, **Sievers C, Lindberg Gasser RL**, Fissolo N, Deisenhammer F, Bocskei Z, Mikol V, Fogdell-Hahn A, Kubala Havrdova E, Broët P, Dönnès P, Mauri C, Jury EC; ABIRISK Consortium. Monocyte NOTCH2 expression predicts IFN- β immunogenicity in multiple sclerosis patients. *JCI Insight*. 2018 Jun 7;3(11). pii: 99274. doi: 10.1172/jci.insight.99274. [Epub ahead of print].IF:pending
2. **Altermatt A, Gaetano L, Magon S**, Haering D, Tomic D, **Wuerfel J, Radue EW, Kappos L, Sprenger T**. Clinical correlations of brain lesion location in multiple sclerosis: voxel-based analysis of a large clinical trial dataset. *Brain Topography* 2018; 31: 886-894. IF17: 2.703
3. Albrecht DS, **Granziera C**, Hooker JM, Loggia ML. Correction to In Vivo Imaging of Human Neuroinflammation. *ACS Chem Neurosci*. 2018;9(6):1515. IF: 4.2
4. **Altermatt A**, Santini F, Deligianni X, **Magon S, Sprenger T, Kappos L**, Cattin P, **Wuerfel J, Gaetano L**. Design and construction of an innovative brain phantom prototype for magnetic resonance imaging. *Magn Reson Med* 2018; 1-7. IF17: 4.082
5. Arnold M, **Engelter S, Lyrer P, Renaud S**, Michel P and Nedeltchev K. Certification of stroke centre and stroke units in Switzerland. *Clinical and Translational Neuroscience*. 2018; 2:2514183X1773840. IF pending
6. Babiloni C, Del Percio C, Lizio R, Noce G, Lopez S, Soricelli A, Ferri R, Pascarelli MT, Catania V, Nobili F, Arnaldi D, Famà F, Orzi F, Buttinelli C, Giubilei F, Bonanni L, Franciotti R, Onofrj M, Stirpe P, **Fuhr P, Gschwandtner U**, Ransmayr G, Fraioli L, Parnetti L, Farotti L, Pievani M, D'Antonio F, De Lena C, Güntekin B, Hanoğlu L, Yener G, Emek-Savaş DD, Triggiani AI, Taylor JP, McKeith I, Stocchi F, Vacca L, Frisoni GB, De Pandis MF. Levodopa may affect cortical excitability in Parkinson's disease patients with cognitive deficits as revealed by reduced activity of cortical sources of resting state electroencephalographic rhythms. *Neurobiol Aging*. 2019 Jan;73:9-20. Epub 2018 Aug 30. IF: 4.454
7. Babiloni C, Del Percio C, Lizio R, Noce G, Lopez S, Soricelli A, Ferri R, Nobili F, Arnaldi D, Famà F, Aarsland D, Orzi F, Buttinelli C, Giubilei F, Onofrj M, Stocchi F, Stirpe P, **Fuhr P, Gschwandtner U**, Ransmayr G, Garn H, Fraioli L, Pievani M, Frisoni GB, D'Antonio F, De Lena C, Güntekin B, Hanoğlu L, Başar E, Yener G, Emek-Savaş DD, Triggiani AI, Franciotti R, Taylor JP, Vacca L, De Pandis MF, Bonanni L. Abnormalities of resting-state functional cortical connectivity in patients with dementia due to Alzheimer's and Lewy body diseases: an EEG study. *Neurobiol Aging*. 2018 May;65:18-40. Epub 2017 Dec 30. IF: 4.454
8. Babiloni C, Del Percio C, Lizio R, Noce G, Lopez S, Soricelli A, Ferri R, Pascarelli MT, Catania V, Nobili F, Arnaldi D, Famà F, Orzi F, Buttinelli C, Giubilei F, Bonanni L, Franciotti R, Onofrj M, Stirpe P, **Fuhr P, Gschwandtner U**, Ransmayr G, Garn H, Fraioli L, Pievani M, D'Antonio F, De Lena C, Güntekin B, Hanoğlu L, Başar E, Yener G, Emek-Savaş DD, Triggiani AI, Taylor JP, De Pandis MF, Vacca L, Frisoni GB, Stocchi F. Functional cortical source connectivity of resting state electroencephalographic alpha rhythms shows similar abnormalities in patients with mild cognitive impairment due to Alzheimer's and Parkinson's diseases. *Clin Neurophysiol*. 2018 Apr;129(4):766-782. Epub 2018 Jan 31. IF: 3.614

9. Babiloni C, Del Percio C, Lizio R, Noce G, Lopez S, Soricelli A, Ferri R, Pascarelli MT, Catania V, Nobili F, Arnaldi D, Famà F, Aarsland D, Orzi F, Buttinelli C, Giubilei F, Onofri M, Stocchi F, Vacca L, Stirpe P, **Fuhr P, Gschwandtner U**, Ransmayr G, Garn H, Fraioli L, Pievani M, Frisoni GB, D'Antonio F, De Lena C, Güntekin B, Hanoğlu L, Başar E, Yener G, Emek-Savaş DD, Triggiani AI, Franciotti R, Taylor JP, De Pandis MF, Bonanni L. Abnormalities of Resting State Cortical EEG Rhythms in Subjects with Mild Cognitive Impairment Due to Alzheimer's and Lewy Body Diseases. *J Alzheimers Dis*. 2018;62(1):247-268 IF: 3.476
10. Barin L, Kaufmann M, Salmen A, Kamm CP, **Gobbi C, Kuhle J**, Pot C, Chan A, **Czaplinski A**, Ajdacic-Gross V, Rodgers S, Kesselring J, Puhon MA, von Wyl V; Swiss Multiple Sclerosis Registry. Patterns of care for Multiple Sclerosis in a setting of universal care access: A cross-sectional study. *Mult Scler Relat Disord*, 28:17-25, 2018. IF: 3.199
11. Barin L, Salmen A, **Disanto G**, Babačić H, **Calabrese P**, Chan A, Kamm CP, Kesselring J, **Kuhle J, Gobbi C**, Pot C, Puhon MA, von Wyl V; Swiss Multiple Sclerosis Registry (SMSR). The disease burden of Multiple Sclerosis from the individual and population perspective: Which symptoms matter most? *Mult Scler Relat Disord*, 25:112-121, 2018. IF: 3.199
12. **Barro C*, Benkert P*, Disanto G, Tsagkas C, Amann M, Naegelin Y, Leppert D, Gobbi C, Granziera C, Yaldizli Ö, Michalak Z, Wuerfel J, Kappos L, Parmar K, Kuhle J.*** Equal contribution. Serum neurofilament as a predictor of disease worsening and brain and spinal cord atrophy in multiple sclerosis. *Brain*, ahead of print, 2018. IF: 10.848
13. Behrens JR, Wanner J, Kuchling J, Ostendorf L, Harms L, Ruprecht K, Niendorf T, Jarius S, Wildemann B, Gieß RM, Scheel M, Bellmann-Strobl J, **Wuerfel J**, Paul F, **Sinnecker T**. 7 Tesla MRI of Baló's concentric sclerosis versus multiple sclerosis lesions. *Ann Clin Transl Neurol*. 2018 Jun;5(8):900-912. doi: 10.1002/acn3.572. IF: 4.649.
14. **Bendfeldt K**, Taschler B, Gaetano L, Madoerin P, Kuster P, **Mueller-Lenke N, Amann M**, Vrenken H, Wottschel V, Barkhof F, Borgwardt S, Kloepfel S, Wicklein E-M, **Kappos L**, Edan G, Freedman M, Montalban X, Hartung H-P, Pohl C, Sandbrink R, **Sprenger T, Radue EW, Wuerfel J**, Nichols T. MRI-based prediction of clinically definite multiple sclerosis based on SVM and lesion geometry. *Human Brain Mapping* 2018; pp1-14. IF17: 3.719
15. Bigler MB, Hirsiger JR, Recher M, **Mehling M**, Daikeler T, Berger CT. Varicella zoster virus-specific T cell responses in untreated giant cell arteritis: comment on the article by England et al. *Arthritis & Rheumatology (Hoboken, NJ)*. 2018;70(2):318-20. IF: 7.8
16. **Bischof A**, Manigold T, **Barro C**, Heijnen I, Berger CT, **Darfuss T, Kuhle J**, Daikeler T. Serum neurofilament light chain: a biomarker of neuronal injury in vasculitic neuropathy. *Ann Rheum Dis*, 77(7): 1093-1094, 2018. IF: 12.35
17. Boillat Y, Bazin PL, O'Brien K, Fartaria MJ, Bonnier G, Krueger G, van der Zwaag W, **Granziera C**. Surface-based characteristics of the cerebellar cortex visualized with ultra-high field MRI. *Neuroimage*. 2018;172:1-8. IF: 5.4
18. **Bonati LH**, Gregson J, Dobson J, McCabe DJH, Nederkoorn PJ, Van Der Worp HB, De Borst GJ, Richards T, Cleveland T, Müller MD, Wolff T, **Engelster ST, Lyrer PA**, Brown MM, Algra A, Bakke SJ, Baldwin N, Beard J, Bladin C, Bland Jm, Boiten J, Bosiers M, Bradbury AW, Canovas D, Chambers B, Chamorro A, Chataway J, Clifton A, Collins R, Coward L, Czlonkowska A, Davis S, DeJaegher L, Doig D, Dorman P, Ederle J, Featherstone RF, Ferro JM, Gaines P, Gillings-Smith G, Goertler M, Gottsäter A, Hacke W, Halliday A, Hamilton G, Hendriks JMH,

Hill M, Kapelle LJ, Kaste M, Kennedy F, Konrad P, Kool LJS, Koudstaal PJ, Malik I, Markus H, Martin P, Mas J-L, Mccollum C, MCGahan T, Mcguire Aj, Michel P, Molyneux A, Moroney J, Mosch A, Moss J, Naylor R, Peeters A, Roy D, Schultz D, Seriki DM, Shinton RA, Sidhu P, Stewart J, Subramanian G, Sztajzel R, Than PG, Thomas D, Turner E, Van Den Berg JSP, Vanhooren G, Venables G, Wahlgren N, Walker S, Warlow C and Zvan B. Restenosis and risk of stroke after stenting or endarterectomy for symptomatic carotid stenosis in the International Carotid Stenting Study (ICSS): secondary analysis of a randomised trial. *Lancet Neurology*. 2018. IF: 27.138

19. Bonnier G, Fischi-Gomez E, Roche A, Hilbert T, Kober T, Krueger G, **Granziera C**. Personalized pathology maps to quantify diffuse and focal brain damage. *Neuroimage Clin*. 2018. IF: 3.9
20. Boscolo Galazzo I, Brusini L, Obertino S, Zucchelli M, **Granziera C**, Menegaz G. On the Viability of Diffusion MRI-Based Microstructural Biomarkers in Ischemic Stroke. *Front Neurosci*. 2018;12:92. IF: 3.3
21. Bove R, Chitnis T, Cree BA, Tintoré M, **Naegelin Y**, Uitdehaag BM, **Kappos L**, Khoury Sj, Montalban X, Hauser SJ, Weiner HI; SUMMIT Consortium SUMMIT (Serially Unified Multicenter Multiple Sclerosis Investigation): creating a repository of deeply phenotyped contemporary multiple sclerosis cohorts. *Mult Scler* 2018;24(11):1485-1498. IF: 5.280
22. Brandt T, Kloss M, Lindner A, Erhart P, Grond-Ginsbach C And **Engelster ST**. Cervical artery dissection in two monozygotic twin-pairs. *Eur J Neurol*. 2018;25: e1-e2. IF: 4.621
23. Brasier N, **Engelster S**, Kolbitsch T, Tabord A, Knobloch J, Kuhne M, Conen D, **Traenka C**, Kreuzberger T, Vollmin G And Eckstein J. The quest for indicators of paroxysmal atrial fibrillation in sinus rhythm - the DETECT AF trial. *Acta Cardiol*. 2018:1-7. IF: 0.87
24. Bridel C, Koel-Simmelink MJA, Peferoen L, Derada Troletti C, Durieux S, Gorter R, Nutma E, Gami P, Iacobaeus E, Brundin L, **Kuhle J**, Vrenken H, Killestein J, Piersma SR, Pham TV, De Vries HE, Amor S, Jimenez CR, Teunissen CE. Brain endothelial cell expression of SPARCL-1 is specific to chronic multiple sclerosis lesions and is regulated by inflammatory mediators in vitro. *Neuropathol Appl Neurobiol*. 2018 Jun;44(4):404-416 IF : 6.059
25. Brown MM And **Bonati LH**. The fate of severe restenosis after carotid interventions - Authors' reply. *Lancet Neurol*. 2018; 17:843-44. IF: 27.138
26. Buck D, Andlauer Tfm, Igl W, Wicklein EM, Mühlau M, Weber F, Köchert K, Pohl C, Arnason B, Comi G, Cook S, Filippi M, Hartung HP, Jeffery D, **Kappos L**, Barkhof F, Edan G, Freedman MS, Montalbán X, Müller-Myhsok B, Hemmer B, the BEYOND and BENEFIT Study Groups. Effect of HLA-DRB1 alleles and genetic variants on the development of neutralizing antibodies to interferon beta in the BEYOND and BENEFIT trials. *Mult Scler J* 2018; 1-9. IF: 5.280
27. Chawla S, Kister I, **Sinnecker T**, **Wuerfel J**, Brisset JC, Paul F, Ge Y. Longitudinal study of multiple sclerosis lesions using ultra-high field (7T) multiparametric MR imaging. *PLoS One*. 2018 Sep;13(9):e0202918. doi: 10.1371/journal.pone.0202918. IF: 2.766
28. Chen X, Wolf D, Siebourg-Polster J, Czech C, **Bonati U**, Fischer D, Khwaja O, Strahm M. An Objective and Child-friendly Assessment of Arm Function by Using a 3-D Sensor. *J Vis Exp*. 2018 Feb 12;(132). IF : 1.184

29. Chiaro G, Fratila C, Martig F, Zecca C, **Gobbi C**. Relapsing paralytic ileus in multiple sclerosis requiring surgery: a video case report. *Clin Auton Res*. 2018 Nov 10 IF: 1.635
30. Chitnis T, Gonzalez C, Healy BC, Saxena S, Rosso M, **Barro C, Michalak Z**, Paul A, Kivisakk P, Diaz-Cruz C, Sattarnezhad N, Pierre IV, Glanz BI, Tomic D, Kropshofer H, Häring D, **Leppert D, Kappos L**, Bakshi R, Weiner HL, **Kuhle J**. Neurofilament light chain serum levels correlate with 10-year MRI outcomes in multiple sclerosis. *Annal Clin Transl Neurol*, 5:1478-1491, 2018. IF: 4.649
31. Chiu I, Piguet O, Diehl-Schmid J, Riedl L, Beck J, Leyhe T, Holsboer-Trachsler E, Kressig RW, Berres M, Monsch AU, **Sollberger M**. Facial emotion recognition performance differentiates between behavioral variant frontotemporal dementia and major depressive disorder. *J Clin Psychiatry*. 2018 Jan/Feb; 79(1). IF: 5.29
32. Cole JW, Xu H, Ryan K, Jaworek T, Dueker N, Mcardle P, Gaynor B, Cheng YC, O'connell J, Bevan S, Malik R, Ahmed NU, Amouyel P, Anjum S, Bis JC, Crosslin D, Danesh J, **Engelger ST**, Fornage M, Frossard P, Gieger C, Giese Ak, Grond-Ginsbach C, Ho WK, Holliday E, Hopewell J, Hussain M, Iqbal W, Jabeen S, Jannes J, Kamal A, Kamatani Y, Kanse S, Kloss M, Lathrop M, Leys D, Lindgren A, Longstreth WT, Jr., Mahmood K, Meisinger C, Metso TM, Mosley T, Jr., Muller-Nurasyid M, Norrving B, Parati E, Peters A, Pezzini A, Quereshi I, Rasheed A, Rauf A, Salam T, Shen J, Slowik A, Stanne T, Strauch K, Tatlisumak T, Thijs VN, Tiedt S, Traylor M, Waldenberger M, Walters M, Zhao W, Boncoraglio G, Debette S, Jern C, Levi C, Markus H, Meschia J, Rofls A, Rothwell P, Saleheen D, Seshadri S, Sharma P, Sudlow C, Worrall B, Isgc Mcot, Consortium W-, Stine Oc, Kittner Sj And Mitchell BD. Genetics of the thrombomodulin-endothelial cell protein C receptor system and the risk of early-onset ischemic stroke *PLoS One*. 2018; 13:e0206554. IF: 2.766
33. Collongues N, Patte-Mensah C, de Seze J, Mensah-Nyagan AG, **Derfuss T**. Testosterone and estrogen in multiple sclerosis: from pathophysiology to therapeutics. *Expert Rev Neurother*. 2018 Jun;18(6):515-522. IF 3,696
34. Compter A, Schilling S, Vaineau CJ, Goeggel-Simonetti B, Metso TM, Southerland A, Pezzini A, Kloss M, Touze E, Worrall BB, Thijs V, Bejot Y, Reiner P, Grond- Ginsbach C, Bersano A, Brandt T, Caso V, **Lyrer PA, Traenka C**, Lichy C, Martin JJ, Leys D, Sarikaya H, Baumgartner RW, Jung S, **Fischer U, Engelger ST**, Dallongeville J, Chabriat H, Tatlisumak T, Bousser MG, Arnold M, Debette S and Consortium Ca-P. Determinants and outcome of multiple and early recurrent cervical artery dissections. *Neurology*. 2018;91: e769-e80. IF: 7.609
35. **Décard BF**, Pham M., Grimm A. Ultrasound and MRI of nerves for monitoring disease activity and treatment effects in chronic dysimmune neuropathies - Current concepts and future directions. *Clin Neurophysiol*. 2018 Jan;129(1):155-167. IF: 3,614
36. Deisenhammer F, Jank M, Lauren A, Sjödin A, Ryner M, Fogdell-Hahn A, **Sievers C, Lindberg R**, Jensen PE, Sellebjerg F, Christodoulou L, Birchler M, Pallardy M, Auer M, Liblau R; ABIRISK consortium. Prediction of natalizumab anti-drug antibodies persistency. *Mult Scler*. 2018 Jan 1:1352458517753721 IF: 5.280
37. **De Marchis GM**, García-Berrocoso T, Elkind MSV, Katan M. Incorporating Biomarkers into a Stroke Research Career. *Stroke*. 2018 Dec;49(12): e329-e331. IF: 6.239
38. **De Marchis GM**, Katan M, **Barro C, Fladt J, Traenka C, Seiffge DJ, Hert L, Gensicke H, Disanto G**, Sutter R, **Peters N**, Sarikaya H, Goeggel-Simonetti B, El-Koussy M, **Engelger S**,

- Lyrer PA**, Christ-Crain M, Arnold M, **Kuhle J** And **Bonati LH**. Serum neurofilament light chain in patients with acute cerebrovascular events. *Eur J Neurol*. 2018; 25:562-68. IF: 4.621
39. **De Marchis GM**, Schneider J, Weck A, **Fluri F**, **Fladt J**, Foerch C, Mueller B, Luft A, Christ-Crain M, Arnold M And Katan M. Midregional proatrial natriuretic peptide improves risk stratification after ischemic stroke. *Neurology*. 2018; 90:e455-e65. IF: 7.609
40. Depoorter A, Neumann R, **Barro C**, **Fisch U**, Weber P, **Kuhle J**, Wellmann S. Neurofilament Light Chain: Blood Biomarker of Neonatal Neuronal Injury. *Frontiers in Neurology*, 2018. IF: 3.508
41. De Stefano N, Giorgio A, Tintoré M, Pia Amato M, **Kappos L**, Palace J, Yousry T, Rocca MA, Ciccarelli O, Enzinger C, Frederiksen J, Filippi M, Vrenken H, Rovira À; MAGNIMS study group Radiologically isolated syndrome or subclinical multiple sclerosis: MAGNIMS consensus recommendations. *Mult Scler*. 2018; 24(2):214-221. IF: 5.280
42. **Diebold M**, **Sievers C**, Bantug G, **Sanderson N**, **Kappos L**, **Kuhle J**, **Lindberg RLP**, **Derfuss T**. Dimethyl fumarate influences innate and adaptive immunity in multiple sclerosis. *J Autoimmun*. 2018 Jan;86:39-50. IF: 7.607
43. **Disanto G**, Zecca C, MacLachlan S, Sacco R, Handunnetthi L, Meier UC, Simpson A, McDonald L, Rossi A, **Benkert P**, **Kuhle J**, Ramagopalan SV, **Gobbi C**. Prodromal symptoms of multiple sclerosis in primary care. *Ann Neurol*, ahead of print, 2018. IF: 10.244
44. Doerr, J, Wernecke KD, **Wuerfel J**, Bellmann-Strobl J, Siffrin V, Sättler MB, Simons M, Linsa A, Tumani H, Paul F. Disease modification in multiple sclerosis by Flurpiratine - results of a randomized placebo controlled phase II trial. *FRONT NEUROL* 2018; epub ahead of print. IF: 3.508
45. **D'Souza M**, Steinheimer S, Dorn J, Morrison C, Boisvert J, **Kravalis K**, Burggraaff J, Van Munster CE, **Diederich M**, Sellen A, Kamm CP, Dahlke F, Uitdehaag BM, **Kappos L**. Reference videos reduce variability of motor dysfunction assessments in multiple sclerosis. *Mult Scler J Exp Transl Clin*. 2018; 4(3): 2055217318792399. (IF -/ not listed yet)
46. Duering M, Konieczny Mj, Tiedt S, Baykara E, Tuladhar AM, Leijssen EV, **Lyrer P**, **Engelster ST**, Gesierich B, Achmüller M, **Barro C**, Adam R, Ewers M, Dichgans M, **Kuhle J**, De Leeuw F-E and **Peters N**. Serum Neurofilament Light Chain Levels Are Related to Small Vessel Disease Burden. *Journal of Stroke*. 2018; 20:228-38. IF: 4.750
47. Dusek, P, Madai VI, Huelnhagen T, Bahn E, Matej R, Sobesky J, Niendorf T, Acosta-Cabronero J, **Wuerfel J**. The choice of embedding media affects image quality, tissue R2* and susceptibility behaviors in post-mortem brain MR microscopy at 7.0T. *MAGN RESON MED* 2018: epub ahead of print IF: 4.082
48. Dusek P, Skoloudik D, Maskova J, Huelnhagen T, Bruha R, Zahorakova D, Niendorf T, Ruzicka E, Schneider SA, **Wuerfel J**. Brain iron accumulation in Wilson's disease: A longitudinal imaging study during anticopper treatment using 7.0T MRI and transcranial sonography. *J Magn Reson Imaging* 2018; 47(1):282-85. IF: 3.612
49. **Engelster ST** And Kressig RW. Besonderheiten moderner Rehabilitation beim betagten Menschen. *Praxis (Bern 1994)*. 2018;107(4): 193-96. IF pending

50. Erdur H, **Polymeris A**, Grittner U, Scheitz Jf, Tutuncu S, **Seiffge DJ**, Audebert HJ, Nolte CH, **Engelter ST** And Rocco A. A Score for Risk of Thrombolysis-Associated Hemorrhage Including Pretreatment with Statins. *Front Neurol.* 2018; 9:74. IF: 3.508
51. Evers KS, Atkinson A, **Barro C**, **Fisch U**, Pfister M, Huhn EA, Lapaire O, **Kuhle J**, Wellmann S. Neurofilament as Neuronal Injury Blood Marker in Preeclampsia. *Hypertension*, 71(6): 1178-1184, 2018. IF: 6.823
52. Fartaria MJ, Todea A, Kober T, O'Brien K, Krueger G, Meuli R, **Granziera C**, Roche A, Bach Cuadra M. Partial volume-aware assessment of multiple sclerosis lesions. *Neuroimage Clin.* 2018;18:245-53. IF: 3.9
53. Feneberg E, Oeckl P, Steinacker P, Verde F, **Barro C**, Van Damme P, Gray E, Grosskreutz J, Jardel C, **Kuhle J**, Koerner S, Lamari F, Amador MDM, Mayer B, Morelli C, Muckova P, Petri S, Poesen K, Raaphorst J, Salachas F, Silani V, Stubendorff B, Turner MR, Verbeek MM, Weishaupt JH, Weydt P, Ludolph AC, Otto M. Multicenter evaluation of neurofilaments in early symptom onset amyotrophic lateral sclerosis. *Neurology*, 90(1):e22-e30, 2018. IF: 7.609
54. Fernández O, Delvecchio M, Edan G, Fredrikson S, Gionvannoni G, Hartung HP, Havrdova E, **Kappos L**, Pozzilli C, Soerensen PS, Tackenberg B, Vermersch P, Comi G. Survey of diagnostic and treatment practices for multiple sclerosis in Europe, part 2: progressive MS, paediatric MS, pregnancy and general management. *Eur J Neurol.* 2018; 25(5): 739-746. IF: 4.621
55. Findling O, **Rust H**, **Yaldizli Ö**, Timmermans DPH, Scheltinga A, Allum JHJ. Balance Changes in Patients With Relapsing-Remitting Multiple Sclerosis: A Pilot Study Comparing the Dynamics of the Relapse and Remitting Phases. *Front Neurol.* 2018 Aug 21;9:686. IF: 3.508
56. **Fladt J**, Hofmann L, Coslovsky M, Imhof A, **Seiffge DJ**, **Polymeris A**, **Thilemann S**, **Traenka C**, **Sutter R**, Schaer B, Kaufmann BA, **Peters N**, **Bonati LH**, **Engelter ST**, **Lyrer PA** And **De Marchis GM**. Fast-track versus long-term hospitalizations for patients with non-disabling acute ischaemic stroke. *Eur J Neurol.* 2018. IF: 4.621
57. **Fladt J**, **Kronlage C** and **De Marchis GM**. Cerebral White Matter Hyperintensities and Microbleeds in Acute Ischemic Stroke: Impact on Recanalization Therapies. A Review of the Literature. *Neurosci Lett.* 2018; 687:55-64. IF: 2.159
58. **Fuhr P**, **Gschwandtner U**. Decreased alpha2 connectivity in EEG is correlated with the cognitive and psychiatric manifestations of Parkinson's disease. *Clin Neurophysiol.* 2018 Aug;129(8):1712-1713. Epub 2018 Jun 18 IF: 3.614
59. Freedman Ms, Wolinsky JS, Comi G, **Kappos L**, Olsson TP, Miller AE, Thangavelu K, Benamor M, Truffinet P, O'connor PW for the TEMSO and TOWER Study Groups. The efficacy of teriflunomide in patients who received prior disease-modifying treatments: Subgroup analyses of the teriflunomide phase 3 TEMSO and TOWER studies *Mult Scler.* 2018; 24(4): 535-539. IF: 5.280
60. Frick C, Dettinger P, Renkawitz J, Jauch A, Berger CT, Recher M, Schroeder T, **Mehling M**. Nano-scale microfluidics to study 3D chemotaxis at the single cell level. *PloS one.* 2018;13(6):e0198330. IF: 2.7

61. **Gaetano L**, Haering DA, **Radue EW**, **Mueller-Lenke N**, Thakur A, Tomic D, **Kappos L**, **Sprenger T**. Fingolimod effect on gray matter, thalamus, and white matter in patients with multiple sclerosis. *Neurology* 2018; 90(15): e1324-e1332. IF: 8.055
62. **Gensicke H**, Al Sultan As, Strbian D, Hametner C, Zinkstok Sm, Moulin S, Bill O, Zini A, Paden V, Kagi G, Pezzini A, **Seiffge DJ**, **Traenka C**, Raty S, Amiri H, Zonneveld Tp, Lachenmeier R, **Polymeris A**, Roos Yb, Gumbinger C, Jovanovic DR, Curtze S, Sibolt G, Vandelli L, Ringleb PA, Leys D, Cordonnier C, Michel P, **Lyrer PA**, **Peters N**, Tatlisumak T, Nederkoorn Pj, **Engelter ST** And Thrombolysis In Stroke Patients C. Intravenous thrombolysis and platelet count. *Neurology*. 2018; 90:e690-e97. IF: 7.609
63. Glaser A, Stahmann A, Meissner T, Flachenecker P, Horáková D, Zaratin P, Bricchetto G, Pugliatti M, Rienhoff O, Vukusic S, de Giacomoni AC, Battaglia MA, Broła W, Butzkueven H, Casey R, Drulovic J, Eichstädt K, Hellwig K, Iaffaldano P, Ioannidou E, **Kuhle J**, Lycke K, Magyari M, Malbaša T, Middleton R, Myhr KM, Notas K, Orologas A, Otero-Romero S, Pekmezovic T, Sastre-Garriga J, Seelldrayers P, Soilu-Hänninen M, Stawiarz L, Trojano M, Ziemssen T, Hillert J, Thalheim C. Multiple sclerosis registries in Europe - An updated mapping survey. *Mult Scler Relat Disord*, 27:171-178, 2018. IF: 3.199
64. Grond-Ginsbach C, Erhart P, Chen B, Kloss M, **Engelter ST** And Cole JW. Copy Number ariation and Risk of Stroke. *Stroke*. 2018; 49:2549-54. IF: 6.239
65. Grond-Ginsbach C and **Engelter ST**. Genetics of Spontaneous Coronary Artery Dissection Gains New Momentum. *Circ Genom Precis Med*. 2018; 11: e002148. IF: 5.664
66. **Gruntz K**, Blöchliger M, Becker C, Jick SS, **Fuhr P**, Meier Cr, **Rüegg S**. Parkinson's disease and the risk of epileptic seizures. *Ann Neurol* 2018; 83: 363-374. IF: 10.244
67. **Gschwind M**, Van Mierlo P, **Rüegg S**. Little effort with big effect – implementing the new IFCN 2017 reommendations on standard EEGs. *Clin Neurophysiol* 2018; 129: 2433-4. IF: 3.614
68. Härtig F, Ross M, Dammeier NM, Fedtke N, Heiling B, Axer H., **Décard BF**, Auffenberg E, Koch M, Rattay TW, Krumbholz M, Bornemann A, Lerche H, Winter N, Grimm A. Nerve Ultrasound Predicts Treatment Response in Chronic Inflammatory Demyelinating Polyradiculoneuropathy-a Prospective Follow-Up. *Neurotherapeutics*. 2018 Apr;15(2):439-451. IF: 5.719
69. **Hafner P**, Phadke R, Manzur A, Smith R, Jaiser S, Schutz P, Sewry C, Muntoni F, Pitt M. Electromyography and muscle biopsy in paediatric neuromuscular disorders Evaluation of current practice and literature review. *Neuromuscul Disord*. 2018 Oct 31 IF: 2.487
70. Hagens, MH, Burggraff J, Kilsdonk ID, Ruggieri S, Collorone S, Cortese R, Cawley N, Sbardella E, **Andelova M**, **Amann M**, Lieb JM, Pantano P, Lissenberg-Witte BI, Killestein J, Oreja-Guevara C, **Wuerfel J**, Ciccarelli O, Gasperini C, Lukas C, Rovira A, Barkhof F, Wattjes MP. MAGNIMS Study Group. Impact of 3 Tesla MRI on interobserver agreement in clinically isolated syndrome: A MAGNIMS multicenter study. *MSJ* 2018; epub ahead of print, IF: 5.280
71. **Haller V**, Dashti D, **Peters N**. SMART - Not Always Only "Stroke-Like". *Headache* 2018; 58:1465-1468. IF: 3.091

72. Hanff E, **Hafner P**, Bollenbach A, **Bonati U**, Kayacelebi AA, Fischer D, Tsikas D. Effects of single and combined metformin and L-citrulline supplementation on L-arginine-related pathways in Becker muscular dystrophy patients: possible biochemical and clinical implications. *Amino Acids*. 2018 Oct;50(10):1391-1406 IF: 2.906
73. Hanssen H, Minghetti A, **Magon S**, Rossmeissl A, **Rasenack M**, **Papadopoulou A**, Klenk C, Faude O, Zahner L, **Sprenger T**, Donath L. Effects of different endurance exercise modalities on migraine days and cerebrovascular health in episodic migraineurs: A randomized controlled trial. *Scand J Med Sci Sports*. 2018 Mar;28(3):1103-1112 IF: 3.623
74. Hayer SN, Krey I, **Barro C**, Rössler F, Körtvelyessy P, Lemke JR, **Kuhle J**, Schöls L. NfL is a biomarker for Adult-Onset Leukoencephalopathy with Axonal Spheroids and Pigmented Glia. *Neurology*, 91(16):755-757, 2018. IF: 7.609
75. Havrdova E, Arnold DI, Bar-Or A, Comi G, Hartung HP, **Kappos L**, Lublin F, Selmaj K, Traboulsee A, Belachew S, Bennett I, Buffels R, Garren H, Han J, Julian L, Napieralski J, Hauser SL, Giovannoni G. No evidence of disease activity (NEDA) analysis by epochs in patients with relapsing multiple sclerosis treated with ocrelizumab versus interferon β -1a. *Mult Scler J Exp Transl Clin*. 2018; 4(1): 2055217318760642. IF not listed yet
76. Högel H, Rissanen E, **Barro C**, Matilainen M, Nylund M, **Kuhle J**, Airas L. Serum glial fibrillary acidic protein correlates with multiple sclerosis disease severity. *Mult Scler*, 2018. *Mult Scler*. 2018 Dec 20:1352458518819380. doi: 10.1177/1352458518819380. [Epub ahead of print]IF: 5.280
77. Hollinger A, Semmlack S, **De Marchis GM**, Spiegel R, Hunziker S, **Ruegg S**, Marsch S and **Sutter R**. Associations between periodic social events and status epilepticus-An 11-year cohort study. *Epilepsia*. 2018; 59:1381-91. IF: 5.067
78. Horvath A, **Tsagkas C**, Andermatt S, **Pezold S**, **Parmar K**, Cattin P. Spinal Cord Gray Matter-White Matter Segmentation on Magnetic Resonance AMIRA Images with MD-GRU. arXiv preprint arXiv:1808.02408. 2018 Aug 7. IF: n.a
79. Jensen PEH, Warnke C, Ingenhoven K, Piccoli L, Gasis M, Hermanrud C, Fernandez-Rodriguez BM, Ryner M, Kramer D, Link J, Ramanujam R, Auer M, Buck D, Grummel V, Bertotti E, Fissolo N, Oliver-Martos B, Nytrova P, Khalil M, Guger M, Rathmaier S, **Sievers-Stober C**, **Lindberg RLP**, Hässler S, Bachelet D, Aktas O, Donnellan N, Lawton A, Hemmer B, Havrdova EK, Kieseier B, Hartung HP, Comabella M, Montalban X, **Derfuss T**, Sellebjerg F, Dönnies P, Pallardy M, Spindeldreher S, Broët P, Deisenhammer F, Fogdell-Hahn A, Sorensen PS; ABIRISK Consortium. Detection and kinetics of persistent neutralizing anti-interferon-beta antibodies in patients with multiple sclerosis. Results from the ABIRISK prospective cohort study. *J Neuroimmunol*. 2018 Nov 7;326:19-27. IF: 2.655
80. Johnen A, Bürkner PC, Landmeyer NC, Ambrosius B, **Calabrese P**, Motte J, Hessler N, Antony G, König IR, Klotz L, Hoshi MM, Aly L, Groppa S, Luessi F, Paul F, Tackenberg B, Bergh FT, Kümpfel T, Tumani H, Stangel M, Weber F, Bayas A, Wildemann B, Heesen C, Zettl UK, Zipp F, Hemmer B, Meuth SG, Gold R, Wiendl H, Salmen A; German Competence Network Multiple Sclerosis (KKNMS). Can we predict cognitive decline after initial diagnosis of multiple sclerosis? Results from the German National early MS cohort (KKNMS). *J Neurol*. 2018 Dec 4. doi:10.1007/s00415-018-9142-y IF: 3.783

81. **Kappos L**, Arnold D, Bar-Or A, Camm AJ, **Derfuss T**, **Sprenger T**, Davies M, Piotrowska A, Ni P, Harada T. Two-year results from a phase 2 extension study of oral amiselimod in relapsing multiple sclerosis. *Mult Scler* 2018; 24(12):1605-1616. IF: 5.280
82. **Kappos L**, Bar-Or A, Cree BAC, Fox RJ, Giovannoni G, Gold R, Vermersch P, Arnold DL, Arnould S, Scherz T, Wolf C, Wallström E, Dahlke F; EXPAND Clinical Investigators (including **Derfuss T**). Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): a double-blind, randomised, phase 3 study. *Lancet*. 2018 Mar 31;391(10127):1263-1273. IF: 53.254
83. **Kappos L**, Trojano M, Butzkueven H, Wiendl H, Spelman T, Pellegrini F, Chen Y, Dong Q, Koendgen H, Belachew S; on behalf of the Tysabri® Observational Program (TOP) Investigators. Greater sensitivity to multiple sclerosis disability worsening and progression events using a roving versus a fixed reference value in a prospective cohort study. *Mult Scler*. 2018; 24(7):963-973. IF: 5.280
84. Kaufmann M, **Kuhle J**, Puhan MA, Kamm CP, Chan A, Salmen A, Kesselring J, **Calabrese P**, **Gobbi C**, Pot C, Steinemann N, Rodgers S, von Wyl V, Swiss Multiple Sclerosis Registry (SMSR). Factors associated with time from first-symptoms to diagnosis and treatment initiation of Multiple Sclerosis in Switzerland. *Mult Scler J Exp Transl Clin*, 4, 2018. (IF -/ not listed yet)
85. Kamm CP, Muehl S, Mircsof D, Müller S, **Czaplinski A**, Achtnichts L, Stellmes P, Di Virgilio G. Role of Family Planning in Women With Multiple Sclerosis in Switzerland: Results of the Women With Multiple Sclerosis Patient Survey. *Front Neurol*. 2018 Oct 10;9:821. eCollection 2018. IF: 3.508
86. Kellert L, Grau A, Pezzini A, Debette S, Leys D, Caso V, Thijs VN, Bersano A, Touze E, Tatlisumak T, **Traenka C**, **Lyrer PA**, **Engelster ST**, Metso Tm, Grond-Ginsbach C, Kloss M, Cervical Artery And Ischemic Stroke Patients -Study G. University education and cervical artery dissection. *J Neurol*. 2018; 265:1065-70. IF: 3.78
87. Kellinghaus C, Rossetti AO, Trinka E, Lang N, Unterberger I, **Rüegg S**, Tilz C, Uzelac Z, Rosenow F. SENSE registry for status epilepticus. *Epilepsia* 2018; 59 (Suppl 2): S150-S154. IF: 5.067
88. Khalil M, Teunissen CE, Otto M, Piehl F, Sormani MP, Gattringer T, **Barro C**, **Kappos L**, Comabella M, Fazekas F, Petzold A, Blennow K, Zetterberg H, **Kuhle J**. Neurofilaments as biomarkers in neurological disorders. *Nat Rev Neurol*, 14(10):577-589, 2018. IF: 19.819
89. Kister I, Spelman T, Patti F, Duquette P, Trojano M, Izquierdo G, Lugaesi A, Grammond P, Sola P, Ferraro D, Grand Maison F, Alroughani R, Terzi M, Boz C, Hupperts R, Lechner-Scott J, **Kappos L**, Pucci E, Hodgkinson, Solaro C, Butzkueven H. Predictors of relapse and disability progression in MS patients who discontinue disease-modifying therapy. *J Neurol Sci*. 2018; 391: 72-76. IF17: 2.285
90. Kita M, Fox RJ, Gold R, Giovannoni G, Phillips JT, Sarda SP, Kong J, Viglietta V, Sheikh Si, Okwuokenye M, **Kappos L**. Corrigendum to 'Effects of Delayed-Release Dimethyl Fumarate(DMF) on Health-Related Quality of Life in Patients With Relapsing-Remitting Multiple Sclerosis: An Integrated Analysis of the Phase 3 DEFINE and CONFIRM Studies. *Clin Ther* 2018;40(5):812 IF: 3.185
91. **Kronlage C**, **Papadopoulou A** and **De Marchis GM**. Isolated oculomotor palsy due to acute ischemic midbrain stroke. *Acta Neurol Belg*. 2018. IF: 2.072

92. Kurmann R, **Engelter ST**, Michel P, Luft AR, Wegener S, Branscheidt M, Eskioglou E, Sirimarco G, **Lyrer PA**, **Gensicke H**, Horvath T, Fischer U, Arnold M And Sarikaya H. Impact of Smoking on Clinical Outcome and Recanalization after Intravenous Thrombolysis for Stroke: Multicenter Cohort Study. *Stroke*. 2018; 49:1170-75. IF: 6.239
93. **Lorscheider J**, **Benkert P**, Lienert C, Hänni P, **Derfuss T**, **Kuhle J**, **Kappos L**, **Yaldizli Ö**. Comparative analysis of natalizumab versus fingolimod as second-line treatment in relapsing-remitting multiple sclerosis. *Mult Scler. J* 2018 ;24(6):777-785. IF: 5.280
94. **Lorscheider J**, **Kuhle J**, Izquierdo G, Lugaresi A, Havrdova E, Horakova D, Hupperts R, Duquette P, Girard M, Prat A, Grand'Maison F, Grammond P, Sola P, Ferraro D, Trojano M, Ramo-Tello C, Lechner-Scott J, Pucci E, Solaro C, Slee M, Van Pesch V, Sanchez Menoyo JL, van der Walt A, Butzkueven H, **Kappos L**, Kalincik T; MSBase Study Group. Anti-inflammatory disease-modifying treatment and disability progression in primary progressive multiple sclerosis: a cohort study. *Eur J Neurol*, 26:363-370, 2018. IF: 4.621
95. Malik R, Chauhan G, Traylor M, Sargurupremraj M, Okada Y, Mishra A, Rutten- Jacobs L, Giese AK, Van Der Laan SW, Gretarsdottir S, Anderson CD, Chong M, Adams HHH, Ago T, Almgren P, Amouyel P, Ay H, Bartz TM, Benavente Or, Bevan S, Boncoraglio Gb, Brown RD, Jr., Butterworth As, Carrera C, Carty Cl, Chasman Di, Chen WM, Cole JW, Correa A, Cotlarciuc I, Cruchaga C, Danesh J, De Bakker PIW, Destefano AL, Den Hoed M, Duan Q, **Engelter ST**, Falcone GJ, Gottesman RF, Grewal RP, Gudnason V, Gustafsson S, Haessler J, Harris TB, Hassan A, Havulinna AS, Heckbert SR, Holliday EG, Howard G, Hsu FC, Hyacinth HI, Ikram MA, Ingelsson E, Irvin MR, Jian X, Jimenez-Conde J, Johnson JA, Jukema JW, Kanai M, Keene Kl, Kissela BM, Kleindorfer DO, Kooperberg C, Kubo M, Lange LA, Langefeld CD, Langenberg C, Launer LJ, Lee JM, Lemmens R, Leys D, Lewis CM, Lin WY, Lindgren AG, Lorentzen E, Magnusson PK, Maguire J, Manichaikul A, Mcardle Pf, Meschia JF, Mitchell Bd, Mosley Th, Nalls MA, Ninomiya T, O'donnell MJ, Psaty Bm, Pulit Sl, Rannikmae K, Reiner AP, Rexrode KM, Rice K, Rich SS, Ridker PM, Rost NS, Rothwell PM, Rotter JI, Rundek T, Sacco RI, Sakaue S, Sale MM, Salomaa V, Sapkota BR, Schmidt R, Schmidt CO, Schminke U, Sharma P, Slowik A, Sudlow CLM, Tanislav C, Tatlisumak T, Taylor KD, Thijs VNS, Thorleifsson G, Thorsteinsdottir U, Tiedt S, Trompet S, Tzourio C, Van Duijn CM, Walters M, Wareham NJ, Wassertheil- Smoller S, Wilson JG, Wiggins Kl, Yang Q, Yusuf S, Bis JC, Pastinen T, Ruusalepp,Schadt EE, Koplev S, Bjorkegren JLM, Codoni V, Civelek M, Smith NL, Tregouet DA, Christophersen IE, Roselli C, Lubitz SA, Ellinor PT, Tai ES, Kooner JS, Kato N, He J, Van Der Harst P, Elliott P, Chambers JC, Takeuchi F, Johnson AD, Sanghera DK, Melander O, Jern C, Strbian D, Fernandez-Cadenas I, Longstreth WT, Jr., Rolfs A, Hata J, Woo D, Rosand J, Pare G, Hopewell JC, Saleheen D, Stefansson K, Worrall BB, Kittner SJ, Seshadri S, Fornage M, Markus HS, Howson JMM, Kamatani Y, Debette S, Dichgans M, Malik R, Chauhan G, Traylor M, Sargurupremraj M, Okada Y, Mishra A, Rutten-Jacobs L, Giese Ak, Van Der Laan Sw, Gretarsdottir S,Anderson CD, Chong M, Adams HHH, Ago T, Almgren P, Amouyel P, Ay H, Bartz TM, Benavente OR, Bevan S, Boncoraglio GB, Brown RD, Jr., Butterworth AS, Carrera C, Carty Cl, Chasman DI, Chen WM, Cole JW, Correa A, Cotlarciuc I, Cruchaga C, Danesh J, De Bakker PIW, Destefano AL, Hoed MD, Duan Q, **Engelter ST**, Falcone GJ, Gottesman RF, Grewal RP, Gudnason V, Gustafsson S, Haessler J, Harris TB, Hassan A, Havulinna As, Heckbert SR, Holliday EG, Howard G, Hsu FC, Hyacinth HI, Ikram MA, Ingelsson E, Irvin MR, Jian X, Jimenez-Conde J, Johnson JA, Jukema JW, Kanai M, Keene Kl, Kissela Bm, Kleindorfer DO, Kooperberg C, Kubo M, Lange LA, Langefeld CD, Langenberg C, Launer LJ, Lee JM, Lemmens R, Leys D, Lewis CM, Lin WY, Lindgren AG, Lorentzen E, Magnusson PK, Maguire J, Manichaikul A, Mcardle Pf, Meschia JF, Mitchell Bd, Mosley TH, Nalls MA, Ninomiya T, O'donnell MJ, Psaty BM, Pulit SL, Rannikmae K, Reiner Ap, Rexrode KM, Rice K, Rich SS, Ridker PM, Rost NS, Rothwell PM, Rotter JI, Rundek T, Sacco RL, Sakaue S, Sale MM, Salomaa V, Sapkota BR, Schmidt R, Schmidt CO, Schminke U, Sharma P, Slowik A, Sudlow

CLM, Tanislav C, Tatlisumak T, Taylor KD, Thijs VNS, Thorleifsson G, Thorsteinsdottir U, Tiedt S, Trompet S, Tzourio C, Van Duijn CM, Walters M, Wareham NJ, Wassertheil-Smoller S, Wilson JG, Wiggins KI, Yang Q, Yusuf S, Amin N, Aparicio HS, Arnett DK, Attia J, Beiser AS, Berr C, Buring JE, Bustamante M, Caso V, Cheng YC, Choi SH, Chowhan A, Cullell N, Dartigues JF, Delavaran H, Delgado P, Dorr M, Engstrom G, Ford I, Gurpreet WS, Hamsten A, Heitsch L, Hozawa A, Ibanez L, Ilinca A, Ingelsson M, Iwasaki M, Jackson RD, Jood K, Jousilahti P, Kaffashian S, Kalra L, Kamouchi M, Kitazono T, Kjartansson O, Kloss M, Koudstaal PJ, Krupinski J, Labovitz DL, Laurie CC, Levi CR, Li L, Lind L, Lindgren CM, Lioutas V, Liu YM, Lopez OL, Makoto H, Martinez-Majander N, Matsuda K, Minegishi N, Montaner J, Morris AP, Muino E, Muller-Nurasyid M, Norrving B, Ogishima S, Parati EA, Peddareddygari LR, Pedersen NL, Pera J, Perola M, Pezzini A, Pileggi S, Rabionet R, Riba-Llena I, Ribases M, Romero JR, Roquer J, Rudd AG, Sarin AP, Sarju R, Sarnowski C, Sasaki M, Satizabal CI, Satoh M, Sattar N, Sawada N, Sibolt G, Sigurdsson A, Smith A, Sobue K, Soriano-Tarraga C, Stanne T, Stine OC, Stott DJ, Strauch K, Takai T, Tanaka H, Tanno K, Teumer A, Tomppo L, Torres-Aguila NP, Touze E, Tsugane S, Uitterlinden AG, Valdimarsson EM, Van Der Lee SJ, Volzke H, Wakai K, Weir D, Williams SR, Wolfe CDA, Wong Q, Xu H, Yamaji T, Sanghera DK, Melander O, Jern C, Strbian D, Fernandez-Cadenas I, Longstreth WT, Jr., Rolfs A, Hata J, Woo D, Rosand J, Pare G, Hopewell JC, Saleheen D, Stefansson K, Worrall BB, Kittner S, Seshadri S, Fornage M, Markus HS, Howson JMM, Kamatani Y, Debette S, Dichgans M, Consortium AF, Cohorts For H, Aging Research In Genomic Epidemiology C, International Genomics Of Blood Pressure C, Consortium I, Starnet, Biobank Japan Cooperative Hospital G, Consortium C, Consortium E-C, Consortium Ep-I, International Stroke Genetics C, Consortium M, Neurology Working Group Of The Cc, Network Nsg, Study Ukyld, Consortium M And Consortium M. Multiancestry genome-wide association study of 520,000 subjects identifies 32 loci associated with stroke and stroke subtypes. *Nat Genet.* 2018; 50:524-37. IF: 27.125

96. Miller DH, Lublin F, Pia Sormani M, **Kappos L**, **Yaldizli Ö**, Freedman Ms, Cree B, Weiner HI, Lubetzki C, Hartung HP, Montalban X, Uitdehaag BM, Macmanus D, Youstry T, Gandini Wheeler-Kingshott C, Li B, Putzki N, Merschhemke M, Häring D, Wolinsky JS. Brain atrophy and disability worsening in primary progressive multiple sclerosis: insights from the INFORMS study. *Ann Clin Transl Neurol.* 2018; 5(3): 346-356. IF: 4.649
97. Montalban X, Gold R, Thompson AJ, Otero-Romero S, Amato MP, Chandraratna D, Clanet M, Comi G, **Derfuss T**, Fazekas F, Hartung HP, Havrdova E, Hemmer B, **Kappos L**, Liblau R, Lubetzki C, Marcus E, Miller DH, Olsson T, Pilling S, Selmaj K, Siva A, Sorensen PS, Sormani MP, Thalheim C, Wiendl H, Zipp F.ECTRIMS/EAN guideline on the pharmacological treatment of people with multiple sclerosis. *Eur J Neurol.* 2018 Feb;25(2):215-237. IF: 4.621
98. Montalban X, Gold R, Thompson AJ, Otero-Romero S, Amato MP, Chandraratna D, Clanet M, Comi G, **Derfuss T**, Fazekas F, Hartung HP, Havrdova E, Hemmer B, **Kappos L**, Liblau R, Lubetzki C, Marcus E, Miller DH, Olsson T, Pilling S, Selmaj K, Siva A, Sorensen PS, Sormani MP, Thalheim C, Wiendl H, Zipp F.ECTRIMS/EAN Guideline on the pharmacological treatment of people with multiple sclerosis. *Mult Scler.* 2018 Feb;24(2):96-120. IF: 5.28
99. Muller MD, Von Felten S, Algra A, Becquemin JP, Brown M, Bulbulia R, Calvet D, Eckstein HH, Fraedrich G, Halliday A, Hendrikse J, Gregson J, Howard G, Jansen O, Mas JI, Brott TG, Ringleb PA, **Bonati LH** And Carotid Stenosis Trialists C. Immediate and Delayed Procedural Stroke or Death in Stenting versus Endarterectomy for Symptomatic Carotid Stenosis. *Stroke.* 2018; 49:2715-22. IF: 6.239
100. **Naegelin Y**, Dingsdale H, Säuberli K, Schädelin S, **Kappos L**, Barde YA. Measuring and validating the levels of brain-derived neurotrophic factor in human serum. *eNeuro* 2018; 5(2) IF: -

101. **Naegelin Y, Rasenack M**, Andelova M, Von Felten S, **Fischer-Barnicol B, Amann M, Mehling M, Kappos L, Sprenger T, Derfuss T**. Shortening the washout to 4 weeks when switching from natalizumab to fingolimod and risk of disease reactivation in multiple sclerosis. *Mult Scler Relat Disord*. 2018 Jul 6;25:14-20. IF: 3.199
102. Nakamura, Y., **Gaetano L**, Matsushita T, Anna A, **Sprenger T, Radue EW, Wuerfel J**, Bauer L, **Amann M**, Shinoda K, Isobe N, Yamasaki R, Saida T, **Kappos L**, Kira JI. A comparison of brain magnetic resonance imaging lesions in multiple sclerosis by race with reference to disability progression. *J Neuroinflamm* 2018; 15(1):255 IF: 5.193
103. Neuhaus M, Bagutti S, **Yaldizli Ö**, Zwahlen D, Schaub S, Frey B, **Fischer-Barnicol B**, Burgunder JM, Martory MD, Pöttgen J, Annoni JM, Penner IK. Characterization of social cognition impairment in multiple sclerosis. *Eur J Neurol*. 2018 Jan;25(1):90-96. IF: 4,621
104. Neuhaus M, **Calabrese P**, Annoni JM. Decision-Making in Multiple Sclerosis Patients: A Systematic Review. *Mult Scler Int*. 2018 Mar 12;2018:7835952. doi: 10.1155/2018/7835952. eCollection 2018. Review. PubMed PMID: 29721338; PubMed Central PMCID: PMC5867562 IF: -
105. **Papadopoulou A.**, Oertel FC, **Gaetano L**, Kuchling J, Zimmermann H, Borisow N, Bellmann-Strobl J, Ruprecht K, Scheel M, **Magon S, Wuerfel J**, Paul F, Brandt AU. Affection of thalamic subnuclei in NMOSD: evidence of anterograde transsynaptic degeneration in the visual pathway. *Multiple Sclerosis Journal* 2018 Oct 1 (Vol. 24, pp. 606-607). IF: 5.280
106. **Parmar K**, Banwell BL, Akbar N, Bigi S. Imaging Pediatric Multiple Sclerosis-Challenges and Recent Advances. *Neuropediatrics*. 2018 Jun;49(3):165-72. IF:1.57
107. **Parmar K**, Stadelmann C, Rocca MA, Langdon D, D'Angelo E, **D'Souza M**, Burggraaff J, Wegner C, Sastre-Garriga J, Barrantes-Freer A, Dorn J, Uitdehaag BMJ, Montalban X, **Wuerfel J**, Enzinger C, Rovira A, Tintore M, Filippi M, **Kappos L, Sprenger T** on behalf of the MAGNIMS group. The role of the cerebellum in multiple sclerosis-150 years after Charcot. *Neuroscience and biobehavioral reviews*. 2018 Jun;89:85-98. IF: 8.29
108. **Peters N** and **Engelter ST**. Crab Sign in Bilateral Extracranial Vertebral Artery Dissection *J Clin Neurol*. 2018; 14:428-29. IF: 2.851
109. Pflueger MO, **Calabrese P**, Studerus E, Zimmermann R, **Gschwandtner U**, Borgwardt S, Aston J, Stieglitz RD, Riecher-Rössler A. The neuropsychology of emerging psychosis and the role of working memory in episodic memory encoding. *Psychol Res Behav Manag*. 2018 May 10;11:157-168. doi: 10.2147/PRBM.S149425. eCollection 2018. PubMed PMID: 29785144 IF: 1.952
110. Pinter D, Gattringer T, Enzinger C, Seifert-Held T, Kneihsl M, Fandler S, Pichler A, **Barro C**, Eppinger S, Pirpamer L, Bachmaier G, Ropele S, Wardlaw JM, **Kuhle J**, Khalil M, Fazekas F. Longitudinal MRI dynamics of recent small subcortical infarcts and possible predictors. *J Cereb Blood Flow Metab*, ahead of print, 2018. IF: 6.045
111. **Polymeris AA**, Albert V, Hersberger KE, **Engelter ST**, Schaedelin S, Arnet L and **Lyrer PA** (2018) Protocol for MAAESTRO: Electronic Monitoring and Improvement of Adherence to Direct Oral Anticoagulant Treatment—a Randomized Crossover Study of an Educational and

Reminder-Based Intervention in Ischemic STROke Patients under Polypharmacy. *Front. Neurol.* 2018; 9:1134. IF: 3.508

112. **Pröbstel AK**, Thanei M, Erni B, Lecourt AC, Branco L, André R, Roux-Lombard P, Koenig KF, Huynh-Do U, Ribí C, Chizzolini C, **Kappos L**, Trendelenburg M, **Derfuss T**. Association of antibodies against myelin and neuronal antigens with neuroinflammation in systemic lupus erythematosus. *Rheumatology (Oxford)*. 2018 Sep 27. IF: 5,245
113. Puhan MA, Steinemann N, Kamm CP, Müller S, **Kuhle J**, Kurmann R, **Calabrese P**, Kesselring J, von Wyl V, Swiss Multiple Sclerosis Registry Smsr. A digitally facilitated citizen-science driven approach accelerates participant recruitment and increases study population diversity. *Swiss Med Wkly*, ahead of print 2018. IF: 1.928
114. Rojas OL*, **Pröbstel AK***, Porfilio P*, Wang A, Charabati M, Sun T, Lee D, Galicia G, Ramaglia V, Ward LA, Leung LYT, Najafi G, Khalegi K, Chiaranunt P, Garcillan B, Li A, Besla R, Naouar I, Cao EY, Yam J, Luck H, Campbell DJ, Allman D, Brooks DG, Tomura M, Baumann R, Zamvil SS, Bar-Or A, Horwitz MS, Winer DA, Mortha A, Mackay F, Prat A, Osborne L, Robbins C, Baranzini SE, Gommerman JL. Recirculating intestinal IgA-producing cells regulate neuroinflammation via IL10. *Cell*. 2018 Dec 21. pii: S0092-8674(18)31560-5. doi: 10.1016/j.cell.2018.11.035. [Epub ahead of print])*contributed equally, IF: 31.398
115. Rossetti Ao, Schindler K, Alvarez V, Sutter R, Novy J, Oddo M, Warpelin-Decrausaz L, **Rüegg S**. Continuous video-EEG randomized controlled trial in adults with altered consciousness. Rationale and study design. *J Clin Neurophysiol* 2018; 35: 359-364. IF: 1.982
116. Schaefer T, Ramadoss A, Leu S, Tintignac L, Tostado C, Bink A, Schurch C, Muller J, Scharer J, Moffa G, Demougin P, Moes S, Stippich C, Falbo S, Neddersen H, Bucher H, Frank S, Jenö P, Lengerke C, **Ritz MF**, Mariani L And Boulay JL. Regulation of glioma cell invasion by 3q26 gene products PIK3CA, SOX2 and OPA1. *Brain Pathol*. 2018. IF: 6.187
117. Scheitz JF, **Gensicke H**, Zinkstok Sm, Curtze S, Arnold M, Hametner C, Pezzini A, Turc G, Zini A, Padjen V, Wegener S, Nordanstig A, Kellert L, Kagi G, Bejot Y, Michel P, Leys D, Nolte CH, Nederkoorn PJ, **Engelter ST** and Collaboration T. Cohort profile: Thrombolysis in Ischemic Stroke Patients (TRISP): a multicentre research collaboration. *BMJ Open*. 2018; 8:e023265. IF: 2.413
118. **Schmidt S**, **Hafner P**, Klein A, Rubino-Nacht D, Gocheva V, Schroeder J, Naduvilekoot Devasia A, Zuesli S, Bernert G, Laugel V, Bloetzer C, Steinlin M, Capone A, Gloor M, Tobler P, Haas T, Bieri O, Zumbunn T, Fischer D, **Bonati U**. Timed function tests, motor function measure, and quantitative thigh muscle MRI in ambulant children with Duchenne muscular dystrophy: A cross-sectional analysis. *Neuromuscul Disord*. 2018 Jan;28(1):16-23 IF: 2.487
119. Schubert V, Bender B, Kinzel N, , **Peters N***, Freilinger T*. A novel *Notch3* frameshift variant – no evidence for a link with CADASIL. *J Neurol* 2018; 265:1338-1342 *equal contributing IF: 3.783
120. Scotti B, **Disanto G**, Sacco R, Guigli M, Zecca C, **Gobbi C**. Effectiveness and safety of Rituximab in multiple sclerosis: an observational study from Southern Switzerland. *PLoS One*. 2018 May 14;13(5):e0197415, IF: 2.766
121. **Seiffge DJ**, Curtze S, Dequatre-Ponchelle N, Pezzini A, Tatlisumak T, Cordonnier C and Werring DJ. Hematoma location and morphology of anticoagulation-associated intracerebral hemorrhage. *Neurology* accepted 15.10.2018 IF: 7.609

122. **Seiffge DJ**, Kagi G, Michel P, Fischer U, Bejot Y, Wegener S, Zedde M, Turc G, Cordonnier C, Sandor PS, Rodier G, Zini A, Cappellari M, Schadelin S, **Polymeris AA**, Werring D, **Thilemann S**, Maestrini I, Berge E, **Traenka C**, Vehoff J, **De Marchis GM**, Kapauer M, **Peters N**, Sirimarco G, **Bonati LH**, Arnold M, **Lyrer PA**, De Maistre E, Luft A, Tsakiris DA, **Engelger ST** and Novel Oral Anticoagulants In Stroke Patients Study G. Rivaroxaban plasma levels in acute ischemic stroke and intracerebral hemorrhage. *Ann Neurol*. 2018; 83:451-59. IF: 10.244
123. **Seiffge DJ**, **Polymeris AA**, **Fladt J**, **Lyrer PA**, **Engelger ST** and **De Marchis GM**. Management of patients with stroke treated with direct oral anticoagulants. *J Neurol*. 2018 Dec;265(12):3022-3033. IF: 3.783
124. **Seiffge DJ**, Werring DJ, Paciaroni M, Dawson J, Warach S, Milling TJ, **Engelger ST**, **Fischer U** and Norrving B. Timing of anticoagulation after recent ischaemic stroke in patients with atrial fibrillation. *Lancet Neurol*. 2018. IF: 27.138
125. Semmlack S, Kaplan PW, Spiegel R, **De Marchis GM**, Hunziker S, Tisljar K, **Rüegg S**, Marsch S, **Sutter R**. Illness severity scoring in status epilepticus-When STESS meets APACHE II, SAPS II, and SOFA. *Epilepsia*. 2018 Dec 25. doi: 10.1111/epi.14623. [Epub ahead of print]. IF: 5.067
126. Siller N, **Kuhle J**, Muthuraman M, Barro C, Uphaus T, Groppa S, **Kappos L**, Zipp F, Bittner S. Serum neurofilament light chain is a biomarker of acute and chronic neuronal damage in early multiple sclerosis. *Mult Scler*, ahead of print, 2018. IF: 5.280
127. **Sinnecker T**, **Granziera C**, **Wuerfel J**, **Schlaeger R**. Future Brain and Spinal Cord Volumetric Imaging in the Clinic for Monitoring Treatment Response in MS. *Curr Treat Options Neurol*. 2018;20(6):17. IF: 2.6
128. Steinemann N, **Kuhle J**, **Calabrese P**, Kesselring J, **Disanto G**, Merkler D, Pot C, Ajdacic-Gross V, Rodgers S, Puhon MA, von Wyl V; Swiss Multiple Sclerosis Registry. The Swiss Multiple Sclerosis Registry (SMSR): study protocol of a participatory, nationwide registry to promote epidemiological and patient-centered MS research. *BMC Neurol*, 18, 2018. IF: 2.17
129. **Sutter R**, Semmlack S, Kaplan PW, Opic P, Marsch S, **Rüegg S**. Prolonged status epilepticus: early recognition and prediction of full recovery. *Epilepsia*. 2018 Nov 22. doi: 10.1111/epi.14603. [Epub ahead of print]. IF: 5.067
130. **Sutter R**, Dittrich T, Semmlack S, **Rüegg S**, Marsch S, Kaplan PW. Systemic and neurological complications of convulsive status epilepticus in adults – from imminent danger to rationale management. *Crit Care Med* 2018; 46: 138-145. IF: 7.050
131. Tatlisumak T, Llinas R, Marti-Fabregas J and **Seiffge DJ**. Deciphering the causes of nontraumatic intracerebral hemorrhage one step at a time. *Neurology* accepted 12.12.2018 IF: 7.609
132. Terziroli Beretta-Piccoli B, Ripellino P, **Gobbi C**, Cerny A, Baserga A, Di Bartolomeo C, Bihl F, Deleonardi G, Melidona L, Grondona AG, Mieli-Vergani G, Vergani D, Muratori L; Swiss Autoimmune Hepatitis Cohort Study Group. Autoimmune liver disease serology in acute hepatitis E virus infection. *J Autoimmun*. 2018 Nov;94:1-6. doi: 10.1016/j.jaut.2018.07.006. Epub 2018 Jul 7, IF: 7.607

133. Thompson AJ, Banwell BL, Barkhof F, Carroll WM, Coetzee T, Comi G, Correale J, Fazekas F, Filippi M, Freedman MS, Fujihara K, Galetta SL, Hartung HP, **Kappos L**, Lublin FD, Marrie RA, Miller AE, Miller DH, Montalban X, Mowry EM, Sorensen PS, Tintoré M, Traboulsee AL, Trojano M, Uitdehaag BMJ, Vukusic S, Waubant E, Weinshenker BG, Reingold SC, Cohen JA. Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria. *Lancet Neurol*. 2018; 17(2):162-173. IF: 27.144
134. Tiedt S, Duering M, **Barro C**, Gizem Kaya A, Boeck J, Bode FJ, Klein M, Dorn F, Gesierich B, Kellert L, Ertl-Wagner B, Goertler M, Petzold GC, **Kuhle J**, Wollenweber FA, **Peters N***, Dichgans M*. Serum Neurofilament Light: A Biomarker of Neuroaxonal Injury after Ischemic Stroke. *Neurology*, 91(14):e1338-e1347, 2018. *equal contributing IF: 7.609
135. Toller G, Brown J, **Sollberger M**, Shdo S, Bouvet L, Sukhanov P, Seeley WW, Miller BL, Rankin KP. Individual differences in socioemotional sensitivity are an index of salience network function. *Cortex*. 2018 Jun; (103) 211-223. IF: 4.27
136. Tomescu MI, Rihs TA, Rochas V, **Hardmeier M**, Britz J, Allali G, **Fuhr P**, Eliez S, Michel CM. From swing to cane: Sex differences of EEG resting-state temporal patterns during maturation and aging. *Dev Cogn Neurosci*. 2018 Jun;31:58-66. Epub 2018 Apr 30, IF:3.417
137. **Traenka C**, Jung S, Gralla J, Kurmann R, Stippich C, Simonetti BG, **Gensicke H**, Mueller H, Lovblad K, Eskandari A, Puccinelli F, Vehoff J, Weber J, Wegener S, Steiner L, Kägi G, Luft A, Sztajzel R, **Fischer U**, **Bonati LH**, **Peters N**, Michel P, **Lyrer PA**, Arnold M, **Engelter ST**. Endovascular therapy versus intravenous thrombolysis in cervical artery dissection ischemic stroke – results from the SWISS registry. *European Stroke Journal* 2018; 3(1):47-56. IF pending
138. Trojano M, Butzkueven H, **Kappos L**, Wiendl H, Spelman T, Pellegrini F, Chen Y, Dong Q, Köndgen H, Belachew S; on behalf of the TOP investigators. Natalizumab treatment shows low cumulative probabilities of confirmed progression to disability EDSS milestones in the long-term setting. *Mult Scler Relat Disord* 2018;24:11-1. IF: 3.199
139. **Tsagkas C**, **Altermatt A**, **Bonati U**, **Pezold S**, Reinhard J, **Amann M**, Cattin P, **Wuerfel J**, Fischer D, **Parmar K***, Fischmann A*. Reliable and fast volumetry of the lumbar spinal cord using cord image analyser (Cordial). *Eur Radiol*. 2018 Nov;28(11):4488-95. PubMed PMID: 29713776. *equal contributing IF: 3.97
140. **Tsagkas C**, **Magon S**, **Gaetano L**, **Petzold S**, **Naegelin Y**, **Amann M**, Stippich C, Cattin P, **Wuerfel J**, **Bieri O**, **Sprenger T**, **Kappos L**, **Parmar K**. Spinal Cord Volume Loss: A Marker of Disease Progression in Multiple Sclerosis. *Neurology*. 2018; 91(4):e349-e358. IF17: 8.055
141. **Tsagkas C**, **Magon S**, **Gaetano L**, **Pezold S**, **Naegelin Y**, **Amann M**, Stippich C, Cattin P, **Wuerfel J**, **Bieri O**, **Sprenger T**, **Kappos L**, **Parmar K**. Preferential spinal cord volume loss in primary progressive multiple sclerosis. *Multiple sclerosis*. 2018:1352458518775006. IF: 5.280
142. Tsvigoulis G, Wilson D, Katsanos AH, Sargento-Freitas J, Marques-Matos C, Azevedo E, Adachi T, Von Der Brelie C, Aizawa Y, Abe H, Tomita H, Okumura K, Hagii J, **Seiffge DJ**, Lioutas Va, **Traenka C**, Varelas P, Basir G, Krogias C, Purrucker Jc, Sharma VK, Rizos T,

- Mikulik R, Sobowale Oa, Barlinn K, Sallinen H, Goyal N, Yeh SJ, Karapanayiotides T, Wu TY, Vadikolias K, Ferrigno M, Hadjigeorgiou G, Houben R, Giannopoulos S, Schreuder F, Chang Jj, Perry La, Mehdorn M, Marto Jp, Pinho J, Tanaka J, Boulanger M, Salman RA, Jager Hr, Shakeshaft C, Yakushiji Y, Choi Pmc, Staals J, Cordonnier C, Jeng JS, Veltkamp R, Dowlatshahi D, **Engelster ST**, Parry-Jones AR, Meretoja A, Mitsias PD, Alexandrov AV, Ambler G And Werring DJ. Neuroimaging and clinical outcomes of oral anticoagulant-associated intracerebral hemorrhage. *Ann Neurol*. 2018. IF: 10.244
143. van Munster CE, **D'Souza M**, Steinheimer S, Kamm CP, Burggraaff J, **Diederich M**, **Kravalis K**, Dorn J, Walsh L, Dahlke F, **Kappos L**, Uitdehaag BM. Tasks of activities of daily living (ADL) are more valuable than the classical neurological examination to assess upper extremity function and mobility in multiple sclerosis. *Mult Scler*. 2018 Aug 31;1352458518796690, IF: 5.280
144. Volkers EJ, Algra A, Kappelle LJ, Jansen O, Howard G, Hendrikse J, Halliday A, Gregson J, Fraedrich G, Eckstein Hh, Calvet D, Bulbulia R, Brown MM, Becquemin JP, Ringleb PA, Mas JL, **Bonati LH**, Brott Tg, Greving Jp And Carotid Stenosis Trialists C. Prediction Models for Clinical Outcome after a Carotid Revascularization Procedure. *Stroke*. 2018; 49:1880-85. IF: 6.239
145. Waje-Andreassen U, Nabavi DG, **Engelster St**, Dippel DW, Jenkinson D, Skoda O, Zini A, Orken DN, Staikov I and **Lyrer P**. European Stroke Organisation certification of stroke units and stroke centres. *European Stroke Journal*. 2018; 3:220-26. IF pending
146. Weber MS, **Derfuss T**, Brück W. Anti-Myelin Oligodendrocyte Glycoprotein Antibody-Associated Central Nervous System Demyelination-A Novel Disease Entity? Editorial *JAMA Neurol*. 2018 Aug 1;75(8):909-910. IF: 11.46
147. Weber MS, **Derfuss T**, Metz I, Brück W. Defining distinct features of anti-MOG antibody associated central nervous system demyelination. *Ther Adv Neurol Disord*. 2018 Mar 29;11:1756286418762083. IF: 4.75
148. Wehrum T, Beume LA, Stich O, Mader I, Mäurer M, **Czaplinski A**, Weiller C, Rauer S. Activation of disease during therapy with alemtuzumab in 3 patients with multiple sclerosis. *Neurology*. 2018 Feb 13;90(7):e601-e605. Epub 2018 Jan 19 IF: 8.055
149. Wilke C, Bender F, Hayer SN, Brockmann K, Schöls L, **Kuhle J**, Synofzik M. Serum neurofilament light is increased in multiple system atrophy of cerebellar type and in repeat-expansion spinocerebellar ataxias: a pilot study. *J Neurol*, 265(7): 1618-1624, 2018. IF: 3.783
150. Wilke C, Rattay TW, Hengel H, Zimmermann M, Brockmann K, Schöls L, **Kuhle J**, Schüle R, Synofzik M. Serum neurofilament light chain is increased in hereditary spastic paraplegias. *Ann Clin Transl Neurol*, 5(7):876-882, 2018. IF: 4.649
151. Wodarg F, Turner El, Dobson J, Ringleb Pa, Mali Wp, Fraedrich G, Chatellier G, Bequemin JP, Brown MM, Algra A, Mas JI, Jansen O, **Bonati LH** and Carotid Stenosis Trialists C. Influence of stent design and use of protection devices on outcome of carotid artery stenting: a pooled analysis of individual patient data. *J Neurointerv Surg*. 2018. IF: 3.524
152. Wolinsky JS, Montalban X, Hauser Sl, Giovannoni G, Vermersch P, Bernasconi C, Deol-Bhullar G, Garren H, P Chin P, Belachew S, **Kappos L**. Evaluation of No Evidence of

Progression or Active Disease (NEPAD) in patients with primary progressive Multiple Sclerosis in the ORATORIO Trial. ANN NEUROL 2018; 84:527–536. IF17: 10.250

153. **Yaldizli Ö**, Sethi V, Pardini M, Tur C, Mok KY, Muhlert N, Liu Z, Samson RS, Wheeler-Kingshott CAM, Yousry TA, Houlden H, Hardy J, Miller DH, Chard DT. Response to the commentary of Yates RL and DeLuca GC on the study: HLA-DRB1*1501 associations with magnetic resonance imaging measures of grey matter pathology in multiple sclerosis. Mult Scler Relat Disord. 2018 Jan;19:168-170. IF: 3.199
154. Zecca C, Roth S, Findling O, Perriard G, Bachmann V, Pless ML, Baumann A, Kamm CP, Lalive PH, **Czaplinski A**. Real-life long-term effectiveness of fingolimod in Swiss patients with relapsing-remitting multiple sclerosis. Eur J Neurol. 2018 May;25(5):762-767. Epub 2018 Mar 6 IF: 4.621
155. Zonneveld Tp, Curtze S, Zinkstok SM, **Gensicke H**, Moulin S, Scheitz JF, **Seiffge DJ**, Hametner C, Heldner MR, **Traenka C**, Erdur H, Baharoglu I, Martinez-Majander N, Pezzini A, Zini A, Padjen V, Correia PN, Strbian D, Michel P, Bejot Y, Arnold M, Leys D, Ringleb PA, Tatlisumak T, Nolte CH, **Engelster ST**, Nederkoorn PJ and Collaborators T. Non-office-hours admission affects intravenous thrombolysis treatment times and clinical outcome. J Neurol Neurosurg Psychiatry. 2018; 89:1005-07. IF: 7.144